TY - JOUR
T1 - The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases
T2 - Update on Therapeutic Strategy Using Natural and Synthetic Compounds
AU - Roy, Tithi
AU - Boateng, Samuel T.
AU - Uddin, Mohammad B.
AU - Banang-Mbeumi, Sergette
AU - Yadav, Rajesh K.
AU - Bock, Chelsea R.
AU - Folahan, Joy T.
AU - Siwe-Noundou, Xavier
AU - Walker, Anthony L.
AU - King, Judy A.
AU - Buerger, Claudia
AU - Huang, Shile
AU - Chamcheu, Jean Christopher
N1 - Funding Information:
This research was partially funded by the following grants and funding: a Start-up fund from the University of Louisiana at Monroe (ULM) College of Pharmacy (COP), and a Faculty Research Seed grant #5CALHN-260615 awards from the ULMCOP; a Pilot and a full research project awards from an Louisiana Biomedical Research Network (LBRN)-IDeA Networks of Biomedical Research Excellence (INBRE) award from the National Institute of General Medical Sciences of the National Institutes of Health (NIGMS/NIH) grant number P2O GM103424-18, an LBRN-INBRE-COBRE Administrative Supplement Award from NIGMS/NIH grant 3P20GM103424-18S1, and a Louisiana Board of Regents Support Fund grant LEQSF (2021-24)-RD-A-22 (awarded to JCC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/6
Y1 - 2023/6
N2 - The dysregulated phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway has been implicated in various immune-mediated inflammatory and hyperproliferative dermatoses such as acne, atopic dermatitis, alopecia, psoriasis, wounds, and vitiligo, and is associated with poor treatment outcomes. Improved comprehension of the consequences of the dysregulated PI3K/Akt/mTOR pathway in patients with inflammatory dermatoses has resulted in the development of novel therapeutic approaches. Nonetheless, more studies are necessary to validate the regulatory role of this pathway and to create more effective preventive and treatment methods for a wide range of inflammatory skin diseases. Several studies have revealed that certain natural products and synthetic compounds can obstruct the expression/activity of PI3K/Akt/mTOR, underscoring their potential in managing common and persistent skin inflammatory disorders. This review summarizes recent advances in understanding the role of the activated PI3K/Akt/mTOR pathway and associated components in immune-mediated inflammatory dermatoses and discusses the potential of bioactive natural products, synthetic scaffolds, and biologic agents in their prevention and treatment. However, further research is necessary to validate the regulatory role of this pathway and develop more effective therapies for inflammatory skin disorders.
AB - The dysregulated phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway has been implicated in various immune-mediated inflammatory and hyperproliferative dermatoses such as acne, atopic dermatitis, alopecia, psoriasis, wounds, and vitiligo, and is associated with poor treatment outcomes. Improved comprehension of the consequences of the dysregulated PI3K/Akt/mTOR pathway in patients with inflammatory dermatoses has resulted in the development of novel therapeutic approaches. Nonetheless, more studies are necessary to validate the regulatory role of this pathway and to create more effective preventive and treatment methods for a wide range of inflammatory skin diseases. Several studies have revealed that certain natural products and synthetic compounds can obstruct the expression/activity of PI3K/Akt/mTOR, underscoring their potential in managing common and persistent skin inflammatory disorders. This review summarizes recent advances in understanding the role of the activated PI3K/Akt/mTOR pathway and associated components in immune-mediated inflammatory dermatoses and discusses the potential of bioactive natural products, synthetic scaffolds, and biologic agents in their prevention and treatment. However, further research is necessary to validate the regulatory role of this pathway and develop more effective therapies for inflammatory skin disorders.
KW - PI3K-Akt-mTOR signaling pathway
KW - acne
KW - antioxidants, flavonoids and bioactive natural products/nutraceuticals
KW - atopic dermatitis
KW - biologics and targeted therapy
KW - phytochemicals
KW - psoriasis
KW - skin inflammation
KW - wound healing
UR - http://www.scopus.com/inward/record.url?scp=85163869667&partnerID=8YFLogxK
U2 - 10.3390/cells12121671
DO - 10.3390/cells12121671
M3 - Review article
C2 - 37371141
AN - SCOPUS:85163869667
SN - 2073-4409
VL - 12
JO - Cells
JF - Cells
IS - 12
M1 - 1671
ER -